New England Biolabs, Inc.

New England Biolabs, Inc., headquartered in Ipswich, Massachusetts, manufactures and sells molecular biology reagents, kits, enzymes, and sequencing products to federal agencies as a prime contractor on a full-and-open basis, with no SBA set-aside designations. The company operates as a for-profit manufacturer of goods under primary NAICS 325414 (Biological Product Manufacturing) and related diagnostic and research categories, with a named subsidiary, Biohelix Corporation.

New England Biolabs holds a $10 million single-award Blanket Purchase Agreement with the NIH Office of Logistics and Acquisition Operations effective through January 31, 2027, which serves as the primary vehicle for task orders across NIH institutes. Representative recent prime work includes a $59,478.40 purchase order from the National Heart Lung and Blood Institute for molecular biology reagents and NEBNext library preparation kits (September 2026), a $158,884.80 purchase order from the National Institute on Aging for enzymatic kits for sequencing (March 2024), and a $124,492.25 purchase order from the National Heart Lung and Blood Institute for NEBNext reagents (April 2022). Additional named work spans the National Human Genome Research Institute (multiple awards for NEBNext multiplex oligos and RNA library prep kits), the National Institute of Allergy and Infectious Diseases (reagents and COVID-19 research supplies), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NEBNext kits and depletion reagents), and the Smithsonian Institution (scientific supplies, $13,281.12, August 2025).

Customer concentration is highly concentrated within the Department of Health and Human Services. The top five customer agencies account for 16 percent of awards and 6 percent of combined potential value across the portfolio, with the NIH Office of the Director leading by award count (103 awards, $884 thousand combined potential value), followed by the CDC Pittsburgh (32 awards, $728 thousand), the National Institute of Allergy and Infectious Diseases (20 awards, $391 thousand), the CDC Office of Acquisition Services (14 awards, $321 thousand), and the National Institute on Aging (5 awards, $267 thousand). The portfolio spans 37 distinct federal customer agencies, but the NIH ecosystem represents the dominant funding base.

New England Biolabs places the largest volume of work under the Federal Supply Schedule V797P5506X (121 task orders, $246 thousand combined potential value) and holds multiple NIH BPAs: the primary $10 million NIH Office of Logistics and Acquisition Operations BPA (Blanket Purchase Agreement 75N98024A00061, 10 task orders, $179 thousand), and two legacy BPAs, HHSN263201100018B (67 task orders, $787 thousand) and HHSN263199900050634B (69 task orders, $128 thousand).

Recent activity shows modest growth: the portfolio registered six awards in 2022, six in 2023, twelve in 2024, and ten in 2025, with one award in 2026 to date. The vendor faces minimal near-term recompete exposure—only one award with an ultimate completion date in the next twenty-four months, carrying $59 thousand in potential value. The portfolio spans 1,228 total awards (1,226 prime, 2 sub) with a combined potential value of $39.9 million, of which $13.4 million has been obligated. Subcontract activity is negligible: New England Biolabs serves as a subcontractor to Gap Solutions, Inc. on a NICHD whole-genome sequencing project involving multiplex oligos and DNA library prep kits (December 2025), and as a sub-recipient on a University of Maryland, Baltimore NIH grant studying polymicrobial infectious disease outcomes (April 2023).

Capability framing across the award history centers on life sciences research consumables: NEBNext library preparation kits (RNA and DNA), multiplex oligos for Illumina sequencing platforms, PCR reagents, enzymatic kits (Q5 master mix, exonuclease cleanup, DNA assembly), depletion kits (globin and rRNA), and general biological materials and reagents. The portfolio NAICS distribution reflects this specificity—Biological Product Manufacturing (167 awards), In-Vitro Diagnostic Substance Manufacturing (61 awards), and Research and Development in Biotechnology (8 awards)—with PSC codes dominated by Laboratory Equipment and Supplies (545 awards), Drugs and Biologicals (197 awards), and Chemicals (172 awards).

Created 'by scientists for scientists', New England Biolabs, Inc (NEB) is renowned for consistently providing exceptional product quality and unsurpassed technical support. For over four decades, NEB has been shaping the landscape of bioscience research by discovering, developing and supporting superior research reagents. Today, NEB is the industry leader in the discovery and production of enzymes for molecular biology applications and offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, qPCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis.

NEB is ISO 9001 and ISO 13485 certified.